Merck KGaA, Darmstadt, Germany

In February 2024, C4 Therapeutics and Merck KGaA, Darmstadt, Germany, which operates its healthcare business as EMD Serono in the U.S. and Canada, announced a strategic discovery research collaboration against critical oncogenic proteins that C4T had progressed from within its internal pipeline prior to entering into this collaboration. Under the terms of the agreement, C4T and Merck KGaA, Darmstadt, Germany are collaborating on two targeted protein degradation projects within the KRAS family.  C4T will be responsible for utilizing its proprietary TORPEDO^® platform to discover degraders for the treatment of cancers driven by KRAS mutations. Merck KGaA, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.